Record number of publications for IVT Lab during 2021 and also superb start for the year 2022.

Even if the pandemic has had a tremendous impact on everyday life in our lab in Helsinki we have been able to produce a record number of published articles. We where able to finish many groundbreaking projects relating to cancer during 2020 and 2021 which in turn led to a number of outstanding publications.
Links to the publications are found here below.

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.

Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation

Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment

PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification

β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy

Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin

Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma

Oncolytic Adenoviruses for Cancer Therapy

GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses

Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

Patient-Derived Organoids for Precision Cancer Immunotherapy

Viral Nanoparticles: Cancer Vaccines and Immune Modulators